Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.

PURPOSE To compare the antiviral activity and ocular distribution of first- and second-generation antisense oligonucleotides intended for the treatment of cytomegalovirus (CMV) retinitis. METHODS The antiviral activity of ISIS 13312 and ISIS 2922 (Isis Pharmaceuticals, Inc., Carlsbad, CA) against 10 clinical CMV isolates was compared with a plaque-reduction assay. The ocular pharmacokinetics were compared after intravitreal injection in rabbits (36-90 microg) and monkeys (125-500 microg). Vitreous and/or retina were collected after single and multiple injections to characterize ocular distribution, clearance, and accumulation. Oligonucleotide concentrations were measured by capillary gel electrophoresis and immunohistochemical techniques. RESULTS ISIS 13312 and ISIS 2922 demonstrated comparable antiviral activity that was consistent among the 10 clinical isolates examined (50% inhibitory concentration [IC(50)], <1 microM). Activity was independent of the resistance of CMV isolates to DNA polymerase inhibitors. After intravitreal injection, the kinetics of ISIS 2922 and ISIS 13312 were characterized by clearance from vitreous and distribution to the retina; however, ISIS 2922 was cleared more quickly from the retina than ISIS 13312. The half-life of ISIS 13312 in the monkey retina was approximately 2 months. Retinal concentrations of ISIS 13312 were dose dependent, with approximately a twofold increase in concentration after once-monthly doses compared with single-dose concentrations. Immunohistochemical analysis indicated that both oligonucleotides were efficiently distributed to numerous ocular tissues, including retina, ciliary body, and optic nerve. CONCLUSIONS ISIS 13312 possesses antiviral activity and pharmacokinetic properties that favor its use as a therapeutic agent in treatment of CMV retinitis. The half-life of ISIS 13312 in retina is longer than that of ISIS 2922, potentially allowing for less frequent administration.

[1]  E. Wickstrom.  Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors , 2020 .

[2]  W. Freeman,et al.  Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. , 2000, AIDS.

[3]  K. Stecker,et al.  Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  A. Levin,et al.  Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[5]  A. Levin,et al.  Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[6]  A. Zutshi,et al.  Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[7]  M. Jacobson,et al.  Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. , 1997, The New England journal of medicine.

[8]  A. Levin,et al.  Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. , 1997, Anti-cancer drug design.

[9]  A. Levin,et al.  Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. , 1997, Anti-cancer drug design.

[10]  W. Freeman,et al.  High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. , 1997, The Journal of infectious diseases.

[11]  B. Monia,et al.  Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras* , 1996, The Journal of Biological Chemistry.

[12]  S. Agrawal,et al.  Effect of different chemically modified oligodeoxynucleotides on immune stimulation. , 1996, Biochemical Pharmacology.

[13]  P. D. Cook,et al.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.

[14]  S. Beaucage,et al.  Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach , 1992 .

[15]  Matthew T. Davis,et al.  A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. , 1991, Annals of internal medicine.

[16]  M. Jacobson,et al.  Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. , 1988, Annals of internal medicine.

[17]  W. Freeman,et al.  Cytomegalovirus retinitis and response to therapy with ganciclovir. , 1987, Ophthalmology.

[18]  S. Henry,et al.  Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides. , 2001, Investigative ophthalmology & visual science.

[19]  Parenteral Cidofovir for Cytomegalovirus Retinitis in Patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.

[20]  S. Agrawal,et al.  Comparative pharmacokinetics of antisense oligonucleotides. , 1996, Methods in molecular medicine.

[21]  M. Jacobson,et al.  Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. , 1991, The Journal of infectious diseases.